

1 **Running title**

2 Widespread Pain in Chronic Pain Patients.

3

4 **Title**

5 Patients with Concomitant Chronic Neck Pain and Myofascial Pain in Masticatory
6 Muscles Have More Widespread Pain and Distal Hyperalgesia than Patients with
7 Only Chronic Neck Pain.

8

9 **Authors**

10 Daniel Muñoz-García, PT, MSc¹⁻³, Ibai López-de-Uralde-Villanueva, PT, MSc¹⁻⁴;
11 Hector Beltran-Alacreu, PT, MSc¹⁻³; Roy La Touche, PT, MSc¹⁻⁴; Josué Fernández-
12 Carnero, PT, PhD^{2,4,5}.

13

14 **Institutions**

15 1. Department of Physiotherapy, Faculty of Health Science, The Center for Advanced
16 Studies University La Salle. Universidad Autónoma de Madrid, Aravaca, Madrid,
17 Spain.

18 2. Research Group on Movement and Behavioural Science and Study of Pain, The
19 Center for Advanced Studies University La Salle, Universidad Autónoma de
20 Madrid.

21 3. Institute of Neuroscience and Craniofacial Pain (INDCRAN), Madrid, Spain.

22 4. Hospital La Paz Institute for Health Research, IdiPAZ, Madrid, Spain.

23 5. Department of Physical Therapy, Occupational Therapy, Rehabilitation and
24 Physical Medicine, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain.

25

26 **DISCLOSURES**

27 **Acknowledgment of any presentation of this material:**

28 No presentation of this material before.

29 **Acknowledgment of financial support, including grant numbers:**

30 No financial support.

31 **Explanation of any conflicts of interest:**

32 No conflicts of interest.

33

34 **Corresponding author**

35 Daniel Muñoz-García.

36 Faculty of Health Science.

37 The Center for Advanced Studies University La Salle. Universidad Autónoma.

38 Calle la Salle, 10.

39 28023 Madrid.

40 SPAIN.

41 Telephone number: + 34 91 7401980

42 Email address: danimgsan@gmail.com

43

44

45

46

47

48

49

50

51 **ABSTRACT**

52 **Objective:** Insufficient evidence exists to compare widespread pain (WP), pain
53 sensibility, and psychological factors that occur in patients presenting with chronic neck
54 pain (CNP) or a combination of temporomandibular disorder (TMD) and other
55 complaints. The present study compared the pain sensibility and psychological factors
56 of subjects with CNP with those with TMD+CNP.

57 **Design:** Cross-sectional study.

58 **Setting:** Local community.

59 **Subjects:** A nonprobabilistic convenience sample of 86 persons with CNP or TMD was
60 recruited into three groups: CNP, TMD with myofascial pain in masticatory muscles
61 with cocomitant CNP (TMD+CNP), and asymptomatic control groups consisted of 27,
62 29, and 30 participants, respectively.

63 **Methods:** Participants underwent a clinical examination to evaluate WP with
64 computerized assessment based on the pain drawing, pressure pain thresholds (PPT),
65 and psychological factors, which were evaluated using the pain catastrophizing scale
66 (PCS) and the state-trait anxiety inventory (STAI).

67 **Results:** Statistically significant differences were observed between participants with
68 CNP and TMD+CNP for WP ($t = -2.80$, $P < 0.01$, $d = 1.06$). Post hoc analyses only
69 revealed significant differences between TMD+CNP participants and asymptomatic
70 controls for PPT at extratrigeminal areas. Pearson correlation analyses showed a
71 moderate positive association between symptomatic groups within the WP and STAI
72 ($P < 0.05$) and a moderate negative association between PCS and PPT ($P < 0.05$) at the
73 right tibialis muscle.

74 **Conclusions:** TMD+CNP participants had more areas of pain and also showed
75 widespread pain hyperalgesia. Both groups of participants had psychological factors

76 positively associated with STAI and WP; further, PCS and the PPT at the
77 extratrigeminal region were negatively associated with each other in both groups,
78 except for the left tibialis in the TMD+CNP group.

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100 **Key words:** Neck Pain, Orofacial Pain, Widespread Pain, Pain Catastrophizing,

101 Anxiety.

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125 INTRODUCTION

126 Idiopathic chronic neck pain (CNP) is a frequent health problem encountered
127 worldwide. Currently, this condition is considered one of the primary causes of
128 disability (1). Previous research has shown that recovery from idiopathic CNP is poor,
129 with at least half of patients suffering neck pain (NP) involving chronification of pain
130 and disability (2). There are numerous causes and predictors for long-term symptoms of
131 idiopathic CNP, including psychological factors and reported levels of perceived pain
132 (3).

133

134 All of these factors presented together frequently sur- pass trigeminal innervations to
135 the back of the head, which is innervated by the greater occipital nerve (4). This can
136 lead to orofacial pain. These clinical features suggest an overlap between trigeminal and
137 cervical sensory afferent projections in the central nervous system. This overlap likely
138 occurs in the upper cervical segments, such as the trigeminal nucleus caudalis. Several
139 clinical studies have demonstrated trigger points in the neck muscles that are linked to
140 the orofacial region (5,6), as well as the zygapophysial joints of C3–C4 (7).

141 Moreover, in addition to disability, recent studies have noted a significant association
142 between cervical spine impairment and temporomandibular disorders (TMD) (8,9). The
143 severity of TMD increases with NP severity (10). The number of patients suffering from
144 TMD is also increasing (11). However, the prevalence of patients with impairments in
145 the masticatory musculature, temporomandibular joints, or both is very heterogeneous
146 (12).

147

148 These clinical manifestations have been diagnosed frequently as central sensitization.

149 This occurs when there is an expansion of deep neural and cutaneous receptive fields

150 beyond the trigeminal areas. There are also alterations in neuronal properties and spinal
151 nociceptive pathways (13,14) that lead to an expansion of pain in the trigeminal and
152 cervical regions, poor localization of pain, hyperalgesia, mechanical allodynia (15,16),
153 and dysfunction of the descending inhibitory system (17). These symptoms are all
154 strongly influenced by supraspinal processes (18) such as general psychological
155 distress, anxiety, and catastrophizing.

156

157 Recent studies have mapped the spatial extent of body pain drawings associated with
158 alterations in pressure pain thresholds (PPTs) (19). Widespread pain (WP) can be
159 associated with health status (20,21). Moreover, WP and psychosocial issues, such as
160 anxiety and depression, have been reported in pain clinics (22,23).

161

162 Additionally, psychosocial factors are related to the presence of neck and orofacial pain
163 (24). Psychosocial factors play an important role in chronic pain patients. For example,
164 it was shown in a cohort study that stress, negative affect, and coping strategies for pain
165 had a significant impact on TMD patients (25). Similarly, Kindler and colleagues (26)
166 found that anxiety was strongly associated with muscle pain in TMD patients.

167 Psychological characteristics, including somatization, depression, and anxiety, appear to
168 have a significant impact on the prevalence of this impairment (27).

169 Nevertheless, there is insufficient evidence to compare pain sensibility, psychological
170 factors, and WP between patients presenting only with CNP and those with TMD and
171 additional mixed complaints. Having this data could provide relevant information to
172 rehabilitators in clinical settings, which could improve the care of patients with chronic
173 pain. Therefore, our hypothesis is that psychosocial factors and WP are higher in
174 participants with concomitant CNP and myofascial pain in masticatory muscles than in

175 participants with only CNP.

176

177 This study accordingly addressed these two questions: 1) Are there differences in the

178 pain sensibility and psychosocial factors of participants with CNP and those with

179 TMD+CNP? 2) Is widespread pain correlated with psychological state in CNP and

180 TMD+CNP participants?

181

182 **METHODS**

183 We developed a cross-sectional study. This study was conducted as a single-blind

184 experiment. Further, we adhered to the International Recommendations for Reporting

185 Observational Studies in Epidemiology (STROBE) (28) in order to strengthen our

186 study. The protocol was conducted in accordance with the Helsinki Declaration and was

187 approved by the local ethics committee (CSEULS-PI-004/2013).

188

189 The research team was composed of two clinical examiners with over seven years of

190 experience in clinical assessment: One researcher conducted participant group

191 allocation, and the other was a single-blinded evaluator who proceeded with the

192 experiment measurements without knowing the group allocation.

193

194 **Subjects**

195 We recruited a consecutive, nonprobabilistic convenience sample of participants from a

196 local community with CNP and TMD between November 2015 and February 2016; we

197 also recruited asymptomatic subjects for the control group. All participants were be-

198 tween the ages of 18 and 40 years; were recruited from the local community using

199 flyers, posters, and social media (e.g., Facebook); and were encouraged to withdraw

200 from all dietary sources of caffeine and alcohol 48hours prior to the evaluation.
201 Participants with infrequent episodes of tension-type headaches were permitted.

202

203 Symptomatic subjects were selected if they fulfilled the following inclusion criteria:
204 They had experienced pain in the neck region for at least 12 weeks (e.g., neck and/or
205 shoulder pain with symptoms provoked by changes in neck posture or neck movement
206 or palpation of the cervical musculature). Once these criteria were screened, the clinical
207 examiner proceeded with recognition of cervical spinal pain based on the procedures
208 described by Visscher et al. (2000) (29), a Neck Disability Index (NDI) score of at least
209 5 (30), and if they had a pain rating of at least 3 on the numerical pain rating scale
210 (NPRS) over the course of the last three months (31). Subjects were assigned to the
211 TMD+CNP group if they reported orofacial pain diagnosed with myofascial pain
212 following Axis 1 (myofascial pain) of the Research Diagnostic Criteria for TMD (32)
213 and bilateral pain of the temporal and masseter muscles as their primary pain complaint
214 for at least three months.

215

216 Subjects were excluded from the study for any of the following reasons: previous
217 surgery for treatment of TMD pain; history of rheumatoid disease or whiplash trauma;
218 extensive anatomical destruction or deterioration of the temporomandibular joint;
219 diagnosis of pain caused by neuropathic or odontogenic factors; diagnosis of psychosis;
220 or current use of antidepressants or anxiolytics and current use of narcotic pain
221 medication or pregnancy.

222

223 Finally, asymptomatic subjects were excluded if they were taking any medication; they
224 had a history of neck, facial, or head pain; or they had a diagnosis of any systemic
225 disease.

226

227 **Outcomes measured**

228 A validated Spanish version of the Neck Disability Index (NDI) (30), a reliable self-
229 assessment tool consisting of 10 questions for measuring disability in CNP patients on a
230 six-point scale (0 = no disability, 5 = full disability), was completed by all participants.

231

232 *Pain Drawings*

233 To measure the extent of ongoing pain spatially, each participant was asked to fill in a
234 body pain diagram. This exercise, which made use of a diagram printed on a sheet of
235 A4 paper, asked participants to mark all areas in which they experienced pain. To
236 ensure that the participants did not focus only on their most painful areas, the
237 instructions stated, “Indicate all locations in which you feel pain, even if the area is not
238 the location of your most intense pain.” Next, the researcher jointly discussed the pain
239 diagram with each participant to prevent representation errors.

240

241 Later, using an electronically scanned version of the body diagram, we used open-
242 source software (33) to calculate the total body area in each pain diagram, which is
243 highly reliable according to Dos Reis et al. (34). This measurement was obtained by
244 shading the figure systematically from the cranial to caudal sections and from the left to
245 right side of the figure, as described elsewhere in the literature (35). The computerized
246 assessment for measuring the pain areas was easy and did not require significant
247 training. Nevertheless, the first assessments were measured twice to compare the results.

248 Based on the literature, we decided to calculate the percentage pain surface area (PPSA)
249 (36). The data were measured in pixels, transformed to centimeters, and finally
250 represented as a percentage of the shaded body area.

251

252 Additionally, we also analyzed the pain drawing using a quantitative scoring system that
253 assessed the total area shaded as previously described (37). This allowed us to count the
254 number of pain sites in order to evaluate WP (36,38,39). Further, it enabled participants
255 to show us where they had experienced pain during the past week. The pain diagrams
256 were scored manually by attributing one point to each square that contained any
257 marking.

258

259 *Psychological Assessment*

260 To evaluate the participants' propensity to catastrophize about their pain, we used the
261 validated Spanish version (40) of the pain catastrophizing scale (PCS) (41). Participants
262 also completed the State-Trait Anxiety Inventory (STAI), a self-reported assessment
263 with good internal consistency ($\alpha = 0.90$) that includes separate measurements of state
264 (A-state) and trait anxiety (A-trait) (42) and is validated for Spanish participants (43).
265 Participants use a four-point response scale ranging from "almost never" to "almost
266 always" to indicate the extent to which they experience each emotion; higher scores
267 indicate greater anxiety.

268

269 *Pressure-Pain Threshold (PPT)*

270 We assessed PPTs using the minimal amount of pressure that corresponds to a feeling
271 of pain (44). We used a digital algometer (Model FDX 100, Wagner Instruments,
272 Greenwich, CT, USA) to measure pressure point threshold (PPT; kg/cm^2). The pressure

273 was applied at a rate of 0.31 kg/second (45). All of the assessments were carried out in a
274 quiet room. In order to familiarize the participants with the test procedure, pressure was
275 first applied to an area that would not be tested during the study.

276

277 The PPTs were measured bilaterally at the trigeminal and extratrigeminal regions. The
278 order of assessments was randomized between the participants. The masseter point

279 (located 2.5 cm anterior to the tragus and 1.5 cm inferior to the tragus) and temporalis

280 muscles point (located 3 cm above the line between the lateral edge of the eye and the

281 anterior part of the helix on the anterior fibers) were chosen as trigeminal areas (46).

282 The upper trapezius muscle was chosen because it is the most common site of pain for

283 participants with idiopathic CNP. The tibialis anterior point was chosen as a remote

284 distant site. Each location was tested three times; each trial was separated by 30 seconds.

285 The mean of the three trials was calculated and used for the analysis. The reliability of

286 pressure algometry is high (intraclass correlation = .91, 95% confidence interval [CI] =

287 0.82–0.97) (47).

288

289 **Procedure**

290 The study protocol was the same for the CNP subjects, the TMD+CNP subjects, and the

291 asymptomatic control group. All of the participants signed a consent form prior to

292 participating. The examinations were conducted in a quiet, draft-free, temperature-

293 regulated, and humidity-controlled laboratory ($24 \pm 1^\circ\text{C}$, relative humidity 25–35%).

294 This protocol was performed by a single blind evaluator who had not participated in the

295 selection process, administration of the questionnaire, or any of the data-collecting

296 procedures.

297 In order to assess if participants met the inclusion criteria, CNP-related disabilities were
298 first evaluated using the Spanish version of the NDI (30). Next, we evaluated the pain
299 drawings in the different participant groups (Figure 1). Then the PPTs were taken, and
300 finally a battery of questionnaires was completed on the day of the evaluation by each
301 participant. These questionnaires included various questions to self-report demographic
302 data and pain-related disability variables. The sociodemographic questionnaire collected
303 information regarding the following variables: sex, age, and duration of pain. Once the
304 participants had completed all demographic data, they completed the psychological
305 questionnaires of the PCS (40) and STAI (43).

306

307 **Sample size**

308 We conducted a pilot study to determine the effect size between CNP and TMD+CNP
309 participants using pain drawing because previous studies have not investigated this
310 topic. This pilot study included 14 CNP participants and 14 TMD+CNP participants and
311 obtained an effect size (Cohen's d) of 0.93.

312

313 We used the statistical software G*Power 3.1.7 (University of Düsseldorf, Germany)
314 (48) to calculate the sample size needed to complete this study. We opted to use an
315 independent t test in order to detect differences between both symptomatic groups for
316 WP. Moreover, we used an alpha error level of 0.05, a statistical power of 80% ($1-\beta$
317 error), and a large effect size of 0.93 (based on the aforementioned pilot study). A total
318 sample size of 52 participants (26 CNP and 26 TMD+CNP) was estimated to ensure
319 reliability.

320

321

322 **Statistical analysis**

323 All of the data analyses were performed using SPSS for Windows, version 21.0 (SPSS
324 Inc., Chicago, IL, USA). The statistical analyses were conducted at a 95% confidence
325 level; a P value of less than 0.05 was considered statistically significant. We generated
326 descriptive statistics for the sociodemographic, psychosocial, and pain-related disability
327 variables and physical measures. We expressed our results as means and standard
328 deviations (SD) with 95% confidence intervals. We confirmed the normality of the data
329 using the Kolmogorov-Smirnov test.

330

331 To compare the primary outcomes (widespread pain and PPSA) between the two
332 symptomatic groups, we used a Student's t test for independent samples. We calculated
333 effect sizes (Cohen's d) for the outcome variables. According to Cohen's method, the
334 magnitude of the effect was classified as small (0.20–0.49), medium (0.50–0.79), or
335 large (≥ 0.8) (49).

336

337 We used a one-way analysis of variance (ANOVA) to analyze the groups' PPTs and
338 psychosocial variables. Significant ANOVA findings were followed up using a post hoc
339 test and a Bonferroni correction. We calculated the partial eta-squared (η^2_p) as a
340 measurement of the effect size (strength of association) for each main effect and
341 interaction in the ANOVAs. For this analysis, 0.010–0.059, 0.060–0.139, and >0.14
342 represented small, medium, and large effects, respectively (50).

343

344 We examined the relationships among pain sensibility, widespread pain, and
345 psychosocial measures using Pearson correlation coefficients. A Pearson correlation

346 coefficient >0.60 , between 0.30 and 0.60 , and <0.30 indicated high, medium, and low
347 correlations, respectively (51).

348

349 **RESULTS**

350 The study involved 86 participants (27 with CNP, 29 with TMD+CNP, and 30
351 asymptomatic controls). Both symptomatic groups exhibited similar outcomes for
352 cervical pain duration, pain intensity, and neck disability ($P>0.05$). The duration of
353 orofacial pain observed in participants with TMD+CNP was 3.32 ± 4.03 years. The
354 sociodemographic and clinical characteristics of the participants are presented in Table
355 1.

356

357 **Comparisons between groups**

358 There were no statistically significant differences between the symptomatic groups in
359 terms of PPSA ($P>0.05$), except for widespread pain in the body pain diagram ($t = -$
360 2.80 , $P < 0.01$, $d = -1.06$) (Table 2).

361

362 One-way ANOVA revealed significant differences for all the psychosocial
363 measurements (PCS: $F = 4.17$, $P = 0.019$, $g2P = 0.10$; A-state: $F = 9.04$, $P < 0.001$, $g2P$
364 $= 0.19$; and A-trait: $F = 6.02$, $P = 0.004$, $g2P = 0.14$). However, the post hoc analysis
365 revealed only statistically significant differences when comparing the TMD+CNP group
366 with the control group for all of these variables; there was a large effect size ($d\geq 0.9$) for
367 the anxiety variables and a medium effect size for PCS ($d\geq 0.7$) (Table 2).

368

369 The results pertaining to the PPT data are presented in Table 3. We observed statistical
370 differences between the symptomatic groups and asymptomatic individuals for all of

371 the variables ($P < 0.05$), except for the distant area (tibialis muscle) in the CNP group (P
372 > 0.05). Furthermore, we noted differences within the CNP and TMD+CNP groups
373 when the masseter muscle ($d \geq 0.8$, $P < 0.05$), the left trapezius muscle ($d \geq 0.7$, $P <$
374 0.05), and the tibialis muscle ($d \geq 0.9$, $P < 0.05$) data were examined.

375

376 **Correlations analysis**

377 Pearson correlation analysis revealed a moderate positive association between WP and
378 the A-STAI in the CNP group ($r = 0.448$, $P = 0.04$) and with the A-trait in the
379 TMD+CNP group ($r = 0.417$, $P = 0.03$). Participants with a higher anxiety score
380 displayed a greater extent of pain.

381

382 Additionally, the TMD+CNP group exhibited an association between WP and orofacial
383 pain chronicity ($r = 0.552$, $P < 0.01$). Finally, PCS was associated with the NDI in the
384 CNP and TMD+CNP groups ($r = 0.494$, $P = 0.01$, and $r = 0.404$, $P = 0.04$, respectively).

385 The other correlations are listed in Table 4.

386

387 **DISCUSSION**

388 Our primary objective was to analyze the pain sensibility and psychosocial factors
389 associated with different symptomatic groups. Our results revealed statistical
390 differences among symptomatic groups when the PPTs at extratrigeminal sites, the left
391 trapezius, and bilateral masseters were measured. When we examined the data obtained
392 at the distant point (tibialis muscle), we noted large effect size differences that exceeded
393 the minimum detectable change (52). This central and peripheral sensitization was
394 noted previously by a few research studies as a potential mechanism to explain the pain
395 in patients with neck pain (53) and other chronic pain (54); it may represent altered

396 processing within descending pathways from the brain (e.g., descending facilitation or
397 loss of descending inhibition) (55). Moreover, a recent systematic review presented a
398 lack of central sensitization in idiopathic neck pain conditions (56), which is consistent
399 with our results. Nevertheless, TMD patients frequently report central sensitization,
400 which manifests clinically as increased pain in the trigeminal and cervical areas, poor
401 localization of pain and hyperalgesia, and descending inhibitory system dysfunction
402 (57–59). These findings are consistent with our results. Furthermore, the authors found
403 statistical differences between the TMD+CNP group and the asymptomatic subjects
404 when examining all of the psychosocial variables. These medium-to-large effect sizes
405 maybe clinically relevant (60).

406

407 When comparing the pain drawings among participants, we did not observe any
408 statistically significant differences in the PPSAs of each group. Nevertheless,
409 widespread pain persisted in more areas in participants in the TMD+CNP group; this
410 difference was significant and had a large effect size. Although the PPSAs of both
411 groups were similar, the number of pain sites could be a key factor that contributes to
412 sensitization differences between the groups. However, the present study is a cross-
413 sectional study, so the results may not provide information about cause-and-effect
414 relationships.

415

416 The secondary objective of this study was to analyze the associations between
417 widespread pain and the physiological state of participants suffering from CNP and
418 TMD. In the CNP group, WP was associated with the A- state variable. Anxious
419 individuals may perceive more situations, such as interpersonal situations involving a
420 threat to one's self-esteem or new or difficult tasks, as threatening, which may result in

421 a corresponding increase in their anxiety state. Furthermore, the group of participants
422 with TMD+CNP had associated WP with trait anxiety, which is most likely influenced
423 by past experiences and a propensity to respond with anxiety in the anticipation of a
424 challenging situation. In contrast to these results, a systematic review by Carnes et al.
425 (2006) (61) concluded that the available data did not support the hypothesis that pain
426 drawings were associated with the psychological state. This finding is inconsistent with
427 more recent studies such as Visser et al. (36), who found that patients with WP reported
428 “severe” or “extremely severe” levels of anxiety. These findings are largely consistent
429 with epidemiological studies reporting associations between the extent of bodily pain
430 (typically the number of body sites affected) and anxiety, depression, and insomnia
431 (20,39,62). Furthermore, these data were similar in WP patients suffering from stressful
432 events and trauma (63,64). Stress causes psychosocial alterations that are associated
433 with the experience of pain, which could lead to a “pain-tension cycle”; widespread
434 body pain may lead to enhanced central sensitization, not just nociceptive pain (65–67).
435 Finally, we did not find a relationship between WP and sensitization when comparing
436 PPT measurements; other researchers have noted an association with higher
437 hypersensitivity that may be explained by the fact that they explored other chronic
438 conditions like fibromyalgia (68). These data may be of interest to the clinical setting,
439 such as rehabilitators working with TMD+CNP patients. Our results may help
440 practitioners to develop better health care strategies (69).

441

442 Moreover, chronic pain data, which were associated previously with WP (39,70,71), are
443 often collected during clinical interviews to ensure better diagnoses and the best
444 treatment option. These data agree with the moderate associations that we found in our
445 TMD+CNP participants, in whom more areas of pain were associated with increased

446 orofacial chronification. The mechanisms underlying WP are likely complex and are
447 currently poorly understood; there is also growing evidence that genetic factors (72,73)
448 contribute to this condition.

449

450 When examining psychosocial associations, we found that the PCS increased with
451 increased disability due to neck pain. This finding corresponds with previous literature
452 and with the fear avoidance model proposed by Vlaeyen and Linton (3). Cognitive
453 processes, such as pain catastrophizing, are an important variable to consider within the
454 disability and the clinical signs presented by various patients with chronic pain (74,75).
455 A scale of jaw disability would likely provide additional information.

456

457 PCS was related to more pain sensibility in the extratrigeminal areas. This relationship
458 may be due to the central sensitization process in these participants, which was
459 discussed earlier in this section.

460

461 Future research and clinical treatment of this group of subjects should carefully identify
462 patients with WP based on pain drawing analysis and psychosocial factors for specific
463 clinical treatment. Also, future studies should consider the classification of these
464 chronic pain patients with the recent criteria for TMD assessment (DC/TMD) including
465 Axis II.

466

467 It is likely that patient-centered approaches based on the specific needs, values, and
468 beliefs of chronic pain patients could be implemented. Physical assessment and
469 psychosocial functioning can guide a practitioner's approach to empower a patient and
470 boost their self-confidence regarding their decision-making during everyday activities.

471 This type of intervention is successful for reducing anxiety in chronic pain patients (76).
472 Such personalized approaches are not yet discussed in the current treatment guidelines
473 for patients with either neck conditions (77) or TMD (78).

474

475 **Limitations**

476 The samples that we investigated differed regarding sex and age. Recent studies have
477 confirmed that women report more frequent and severe signs of TMD and CNP than
478 men (79,80). The age difference between our sample groups (approximately six years)
479 was not likely to be clinically relevant. Furthermore, we did not assess the contribution
480 of the participants' socioeconomic status. Some studies have found that a lower
481 socioeconomic status modifies the probability of WP in chronic conditions (38).

482

483 We did not control for the recent hypothesis that reduced quantity of vitamin D and
484 physical inactivity are associated with extended body pain (81). We also did not obtain
485 pain drawings at multiple time points throughout the evaluation process, which was
486 recently recommended (82). Nevertheless, we followed other proposed
487 recommendations. Finally, we did not use a specific test to measure the craniofacial
488 disability, which is desirable for future studies.

489

490 **CONCLUSION**

491 Clinicians should be aware that subjects presenting with TMD+CNP likely have
492 differences in pain hyperalgesia at extratrigeminal regions and in psychosocial factors.
493 STAI and widespread pain were positively associated with psychosocial factors in both
494 groups of symptomatic subjects; moreover, PCS and the PPT at the extratrigeminal
495 regions were negatively associated in these groups of subjects, except for the left tibialis

496 in the TMD+CNP group.

497

498

499

500

501 **REFERENCES**

- 502 [1]. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for
503 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for
504 the Global Burden of Disease Study 2010. *Lancet* 2012;380:2163–96.
- 505 [2]. Carroll LJ, Hogg-Johnson S, Côté P, et al. Course and prognostic factors for
506 neck pain in workers: Results of the Bone and Joint Decade 2000-2010 task
507 force on neck pain and its associated disorders. *J Manipulative Physiol Ther*
508 2009;32:S108–16.
- 509 [3]. Vlaeyen JWS, Linton SJ. Fear-avoidance model of chronic musculoskeletal
510 pain: 12 years on. *Pain* 2012;153:1144–7.
- 511 [4]. Piovesan EJ, Kowacs PA, Tatsui CE, et al. Referred pain after painful
512 stimulation of the greater occipital nerve in humans: Evidence of convergence of
513 cervical afferences on trigeminal nuclei. *Cephalalgia* 2001;21:107–9.
- 514 [5]. Wright EF. Referred craniofacial pain patterns in patients with
515 temporomandibular disorder. *J Am Dent Assoc* 2000;131:1307–15.
- 516 [6]. Fernández-de-Las-Peñas C, Galán-Del-Río F, Alonso-Blanco C, et al. Referred
517 pain from muscle trigger points in the masticatory and neck-shoulder
518 musculature in women with temporomandibular disorders. *J Pain* 2010;11:1295–
519 304.
- 520 [7]. Cooper G, Bailey B, Bogduk N. Cervical zygapophysial joint pain maps. *Pain*
521 *Med* 2007;8:344–53.
- 522 [8]. Armijo-Olivo S, Silvestre RA, Fuentes JP, et al. Patients with
523 temporomandibular disorders have increased fatigability of the cervical extensor
524 muscles. *Clin J Pain* 2012;28:55–64.
- 525 [9]. Muñoz-García D, Gil-Martínez A, López-López A, et al. Chronic neck pain and
526 cervico-craniofacial pain patients express similar levels of neck pain- related
527 disability, pain catastrophizing, and cervical range of motion. *Pain Res Treat*
528 2016; in press.
- 529 [10]. Wiesinger B, Malker H, Englund E, Wänman A. Does a dose-response relation
530 exist between spinal pain and temporomandibular disorders? *BMC*
531 *Musculoskelet Disord* 2009;10:28.
- 532 [11]. Resende CM, Alves AC, Coelho LT, et al. Quality of life and general health in
533 patients with temporomandibular disorders. *Braz Oral Res* 2013;27:116–21.
- 534 [12]. Okeson JP, de Leeuw R. Differential diagnosis of temporomandibular disorders
535 and other orofacial pain disorders. *Dent Clin North Am* 2011;55 :105–20.
- 536 [13]. Lam DK, Sessle BJ, Hu JW. Glutamate and capsaicin effects on trigeminal
537 nociception II: Activation and central sensitization in brainstem neurons with
538 deep craniofacial afferent input. *Brain Res* 2009; 1253:48–59.

- 539 [14]. Vernon H, Sun K, Zhang Y, Yu X-M, Sessle BJ. Central sensitization induced in
540 trigeminal and upper cervical dorsal horn neurons by noxious stimulation of
541 deep cervical paraspinal tissues in rats with minimal surgical trauma. *J*
542 *Manipulative Physiol Ther* 2009;32:506–14.
- 543 [15]. Sessle BJ. Peripheral and central mechanisms of orofacial inflammatory pain.
544 *Int Rev Neurobiol* 2011; 97:179–206.
- 545 [16]. Sessle BJ. Recent insights into brainstem mechanisms underlying craniofacial
546 pain. *J Dent Educ* 2002;66:108–12.
- 547 [17]. Sarlani E, Grace EG, Reynolds MA, Greenspan JD. Evidence for up-regulated
548 central nociceptive processing in patients with masticatory myofascial pain. *J*
549 *Orofac Pain* 2004;18:41–55.
- 550 [18]. Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial
551 approach to chronic pain: Scientific advances and future directions. *Psychol Bull*
552 2007;133:581–624.
- 553 [19]. Gerhardt A, Eich W, Janke S, et al. Chronic widespread back pain is distinct
554 from chronic local back pain: Evidence from quantitative sensory testing, pain
555 drawings, and psychometrics. *Clin J Pain* 2015;32(7):568–79.
- 556 [20]. Ektor-Andersen J, Isacsson SO, Lindgren A, Orbaek P. The experience of pain
557 from the shoulder-neck area related to the total body pain, self-experienced
558 health and mental distress. The Malmö Shoulder-Neck Study group. *Pain*
559 1999;82:289–95.
- 560 [21]. Kamaleri Y, Natvig B, Ihlebaek CM, Benth JS, Bruusgaard D. Number of pain
561 sites is associated with demographic, lifestyle, and health-related factors in the
562 general population. *Eur J Pain* 2008;12:742–8.
- 563 [22]. Gerrits MMJG, van Oppen P, van Marwijk HWJ, Penninx BWJH, van der Horst
564 HE. Pain and the onset of depressive and anxiety disorders. *Pain* 2014;155:53–9.
- 565 [23]. Gupta A, Silman AJ, Ray D, et al. The role of psychosocial factors in predicting
566 the onset of chronic widespread pain: Results from a prospective population-
567 based study. *Rheumatology* 2007;46 :666–71.
- 568 [24]. Rantala MA, Ahlberg J, Suvinen TI, et al. Temporomandibular joint related
569 painless symptoms, orofacial pain, neck pain, headache, and psychosocial
570 factors among non-patients. *Acta Odontol Scand* 2003;61:217–22.
- 571 [25]. Fillingim RB, Ohrbach R, Greenspan JD, et al. Potential psychosocial risk
572 factors for chronic TMD: Descriptive data and empirically identified domains
573 from the OPPERA case-control study. *J Pain* 2011; 12:T46–60.
- 574 [26]. Kindler S, Samietz S, Houshmand M, et al. Depressive and anxiety symptoms as
575 risk factors for temporomandibular joint pain: A prospective cohort study in the
576 general population. *J Pain*. 2012;13 :1188–97.
- 577 [27]. Licini F, Nojelli A, Segù M, Collesano V. Role of psychosocial factors in the

- 578 etiology of temporomandibular disorders: Relevance of a biaxial diagnosis.
579 *Minerva Stomatol* 2009;58:557–66.
- 580 [28]. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of
581 Observational Studies in Epidemiology (STROBE) statement: Guidelines for
582 reporting observational studies. *J Clin Epidemiol* 2008;61.
- 583 [29]. Visscher CM, Lobbezoo F, de Boer W, et al. Clinical tests in distinguishing
584 between persons with or without craniomandibular or cervical spinal pain
585 complaints. *Eur J Oral Sci* 2000;108:475–83.
- 586 [30]. Andrade Ortega JA, Delgado Martínez AD, Almécija Ruiz R. Validation of the
587 Spanish version of the neck disability index. *Spine (Phila Pa 1976)*
588 2010;35:E114–8.
- 589 [31]. Jensen MP, Turner JA, Romano JM, Fisher LD. Comparative reliability and
590 validity of chronic pain intensity measures. *Pain* 1999;83:157–62.
- 591 [32]. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular
592 disorders: Review, criteria, examinations and specifications, critique. *J*
593 *Craniomandib Disord* 1992;6:301–55.
- 594 [33]. GIMP Team. GIMP User Manual; 2009. <http://docs.gimp.org/2.8/en/> (accessed
595 July 1, 2016).
- 596 [34]. Dos Reis FJJ, de Barros E Silva V, de Lucena RN, Mendes Cardoso BA,
597 Nogueira LC. Measuring the pain area: An intra- and inter-rater reliability study
598 using image analysis software. *Pain Pract* 2016;16:24–30.
- 599 [35]. Persson AL, Garametsos S, Pedersen J. Computeraided surface estimation of
600 pain drawings - intra- and inter-rater reliability. *J Pain Res* 2011;4:135–41.
- 601 [36]. Visser EJ, Ramachenderan J, Davies SJ, Parsons R. Chronic widespread pain
602 drawn on a body diagram is a screening tool for increased pain sensitization,
603 psycho-social load, and utilization of pain management strategies. *Pain Pract*
604 2014;16:31–7.
- 605 [37]. Hägg O, Fritzell P, Hedlund R, et al. Pain-drawing does not predict the outcome
606 of fusion surgery for chronic low-back pain: A report from the Swedish Lumbar
607 Spine Study. *Eur Spine J* 2003;12:2–11.
- 608 [38]. Rannestad T, Skjeldestad F. Socioeconomic conditions and number of pain sites
609 in women. *BMC Womens Health* 2012;12: 7.
- 610 [39]. Andersson HI. The course of non-malignant chronic pain: A 12-year follow-up
611 of a cohort from the general population. *Eur J Pain* 2004;8:47–53.
- 612 [40]. Garcia Campayo J, Rodero B, Alda M, et al. [Validation of the Spanish version
613 of the pain catastrophizing scale in fibromyalgia]. *Med Clin* 2008; 131:487–92.
- 614 [41]. Sullivan MJL, Bishop SR, Pivik J. The pain catastrophizing scale: Development
615 and validation. *Psychol Assess* 1995;7:524–32.


- 616 [42]. Spielberger CD, Gorsuch RL, LRE. Manual for the State-Trait Anxiety
617 Inventory. Palo Alto, CA; Consulting Psychologists Press 1970.
- 618 [43]. Spielberger CD, Gorsuch RL LR. STAI, Cuestionario de Ansiedad
619 Estado/Rasgo. TEA ediciones SA, 2001.
- 620 [44]. Vanderweeën L, Oostendorp RAB, Vaes P, Duquet W. Pressure algometry in
621 manual therapy. *Man Ther* 1996;1:258–65.
- 622 [45]. Chesterton LS, Sim J, Wright CC, Foster NE. Interrater reliability of algometry
623 in measuring pressure pain thresholds in healthy humans, using multiple raters.
624 *Clin J Pain* 23:760–6.
- 625 [46]. Linari-Melfi M, Cantarero-Villanueva I, Fernández-Lao C, et al. Analysis of
626 deep tissue hypersensitivity to pressure pain in professional pianists with
627 insidious mechanical neck pain. *BMC Musculoskelet Disord* 2011;12:268.
- 628 [47]. Fernández-de-las-Peñas C, Galán-del-Río F, Fernández-Carnero J, et al.
629 Bilateral widespread mechanical pain sensitivity in women with myofascial
630 temporomandibular disorder: Evidence of impairment in central nociceptive
631 processing. *J Pain* 2009;10:1170–8.
- 632 [48]. Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: A flexible statistical
633 power analysis program for the social, behavioral, and biomedical sciences.
634 *Behav Res Methods* 2007;39:175–91.
- 635 [49]. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. Lawrence
636 Erlbaum Associates, Hillsdale, MI; 1988.
- 637 [50]. Cohen J. Eta-squared and partial eta-squared in fixed factor ANOVA designs.
638 *Educ Psychol Meas* 1973;33:107–12.
- 639 [51]. Hinkle D, Jurs S, Wiersma W. *Applied statistics for the behavioral sciences*. 2nd
640 ed. Boston, MA: Houghton Mifflin; 1988.
- 641 [52]. Walton DM, Macdermid JC, Nielson W, et al. Reliability, standard error, and
642 minimum detectable change of clinical pressure pain threshold testing in people
643 with and without acute neck pain. *J Orthop Sports Phys Ther* 2011;41:644–50.
- 644 [53]. La Touche R, Fernández-de-Las-Peñas C, Fernández-Carnero J, et al. Bilateral
645 mechanical-pain sensitivity over the trigeminal region in patients with chronic
646 mechanical neck pain. *J Pain* 2010;11:256–63.
- 647 [54]. Blumenstiel K, Gerhardt A, Rolke R, et al. Quantitative sensory testing profiles
648 in chronic back pain are distinct from those in fibromyalgia. *Clin J Pain*
649 2011;27:682–90.
- 650 [55]. Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending
651 facilitation. *Trends Neurosci* 2002;25:319–25.
- 652 [56]. Malfliet A, Kregel J, Cagnie B, et al. Lack of evidence for central sensitization
653 in idiopathic, non-traumatic neck pain: A systematic review. *Pain Physician*

- 654 18:223–36.
- 655 [57]. Park JW, Clark GT, Kim YK, Chung JW. Analysis of thermal pain sensitivity
656 and psychological profiles in different subgroups of TMD patients. *Int J Oral*
657 *Maxillofac Surg* 2010;39:968–74.
- 658 [58]. Lorduy KM, Liegey-Dougall A, Haggard R, Sanders CN, Gatchel RJ. The
659 prevalence of comorbid symptoms of central sensitization syndrome among
660 three different groups of temporomandibular disorder patients. *Pain Pract*
661 2013;13:604–13.
- 662 [59]. Carvalho GF, Chaves TC, Florencio LL, et al. Reduced thermal threshold in
663 patients with temporomandibular disorders. *J Oral Rehabil* 2016;43(6):401–8.
- 664 [60]. Tingey R, Lambert M, Burlingame G, Hansen N. Assessing clinical
665 significance: Proposed extensions to method. *Psychother Res* 1996;6:109–23.
- 666 [61]. Carnes D, Ashby D, Underwood M. A systematic review of pain drawing
667 literature: Should pain drawings be used for psychologic screening? *Clin J Pain*
668 2006;22:449–57.
- 669 [62]. Tait RC, Chibnall JT, Margolis RB. Pain extent: Relations with psychological
670 state, pain severity, pain history, and disability. *Pain* 1990;41:295–301.
- 671 [63]. Jones GT, Power C, Macfarlane GJ. Adverse events in childhood and chronic
672 widespread pain in adult life: Results from the 1958 British Birth Cohort Study.
673 *Pain* 2009;143:92–6.
- 674 [64]. Wynne-Jones G, Jones GT, Wiles NJ, Silman AJ, Macfarlane GJ. Predicting
675 new onset of widespread pain following a motor vehicle collision. *J Rheumatol*
676 2006;33:968–74.
- 677 [65]. Rehm SE, Koroschetz J, Gockel U, et al. A cross-sectional survey of 3035
678 patients with fibromyalgia: Subgroups of patients with typical comorbidities and
679 sensory symptom profiles. *Rheumatology* 2010;49:1146–52.
- 680 [66]. Koroschetz J, Rehm SE, Gockel U, et al. Fibromyalgia and neuropathic pain–
681 differences and similarities. A comparison of 3057 patients with diabetic painful
682 neuropathy and fibromyalgia. *BMC Neurol* 2011;11:55.
- 683 [67]. Amris K, Jespersen A, Bliddal H. Self-reported somatosensory symptoms of
684 neuropathic pain in fibromyalgia and chronic widespread pain correlate with
685 tender point count and pressure-pain thresholds. *Pain* 2010;151:664–9.
- 686 [68]. Carli G, Suman AL, Biasi G, Marcolongo R. Reactivity to superficial and deep
687 stimuli in patients with chronic musculoskeletal pain. *Pain* 2002;100:259–69.
- 688 [69]. Pain Australia. National Pain Strategy. Available at:
689 [http://www.painaustralia.org.au/the-national-pain-strategy/national-pain-](http://www.painaustralia.org.au/the-national-pain-strategy/national-pain-strategy.html)
690 [strategy.html](http://www.painaustralia.org.au/the-national-pain-strategy/national-pain-strategy.html); 2011 (accessed June 2016).
- 691 [70]. Staud R, Price DD, Robinson ME, Vierck CJ. Body pain area and pain-related

- 692 negative affect predict clinical pain intensity in patients with fibromyalgia. *J*
693 *Pain* 2004;5:338–43.
- 694 [71]. Krause SJ, Tait RC, Margolis RB. Pain distribution, intensity, and duration in
695 patients with chronic pain. *J Pain Symptom Manage* 1989;4:67–71.
- 696 [72]. Arnold LM, Hudson JI, Hess EV, et al. Family study of fibromyalgia. *Arthritis*
697 *Rheum* 2004;50:944–52.
- 698 [73]. Holliday KL, Nicholl BI, Macfarlane GJ, et al. Genetic variation in the
699 hypothalamic-pituitary-adrenal stress axis influences susceptibility to
700 musculoskeletal pain: Results from the EPIFUND study. *Ann Rheum Dis*
701 2010;69:556–60.
- 702 [74]. Picavet HSJ, Vlaeyen JWS, Schouten JSAG. Pain catastrophizing and
703 kinesiophobia: Predictors of chronic low back pain. *Am J Epidemiol*
704 2002;156:1028–34.
- 705 [75]. Somers TJ, Keefe FJ, Pells JJ, et al. Pain catastrophizing and pain-related fear in
706 osteoarthritis patients: Relationships to pain and disability. *J Pain Symptom*
707 *Manage* 2009;37:863–72.
- 708 [76]. Alamo MM, Moral RR, Pérula de Torres LA. Evaluation of a patient-centred
709 approach in generalized musculoskeletal chronic pain/fibromyalgia patients in
710 primary care. *Patient Educ Couns* 2002;48:23–31.
- 711 [77]. Childs JD, Cleland JA, Elliott JM, et al. Neck pain: Clinical practice guidelines
712 linked to the international classification of functioning, disability, and health
713 from the orthopedic section of the American Physical Therapy Association. *J*
714 *Orthop Sports Phys Ther* 2008;38:A1–34.
- 715 [78]. Durham J. Summary of Royal College of Surgeons' (England) clinical
716 guidelines on management of temporomandibular disorders in primary care. *Br*
717 *Dent J* 2015;218:355–6.
- 718 [79]. Adèrn B, Stenvinkel C, Sahlqvist L, Tegelberg A. Prevalence of
719 temporomandibular dysfunction and pain in adult general practice patients. *Acta*
720 *Odontol Scand* 2014;72:585–90.
- 721 [80]. Schmid-Schwap M, Bristela M, Kundi M, Piehslinger E. Sex-specific
722 differences in patients with temporomandibular disorders. *J Orofac Pain*
723 2013;27:42–50.
- 724 [81]. McBeth J, Pye SR, O'Neill TW, et al. Musculoskeletal pain is associated with
725 very low levels of vitamin D in men: Results from the European Male Ageing
726 Study. *Ann Rheum Dis* 2010;69:1448–52.
- 727 [82]. Hawkins JM, Schmidt JE, Hargitai IA, et al. Multimodal assessment of body
728 pain in orofacial pain patients. *Pain Med* 2016; in press.
- 729

Figure 1. Pain drawing.

A) Chronic neck pain group pain drawing group



B) Temporomandibular disorder with chronic neck pain group pain drawing




Table 1. Descriptive data of participants and clinical characteristics of patient groups.

	Mean \pm SD			P
	CNP (N= 27)	TMD+CNP (N= 29)	Asymptomatic (N=30)	
Age, mean SD, y	27.52 \pm 4.82	33.21 \pm 6.69	26.51 \pm 4.51	<0.001*
Gender, female:male	17:10	26:3	17:13	0.014†
NPRS	5.67 \pm 1.89	6.02 \pm 3.22	–	0.635‡
NDI	23.11 \pm 7.69	26.41 \pm 10.03	–	0.171‡
Pain duration, y	2.84 \pm 3.03	1.75 \pm 2.08	–	0.278‡

CNP, chronic neck pain; NPRS, numerical pain rating scale; NDI, Neck Disability Index; TMD, temporomandibular disorder.

*One-way analysis of variance.

†Chi-square tests.

‡Independent Student's test.

Table 2. Descriptive data and multiple comparisons of pain drawings and psychological.

	Mean \pm SD			Mean difference (95% CI), effect size (<i>d</i>)
	CNP	TMD+CNP	Asymptomatic	
Widespread pain UB	12.69 \pm 6.90	26.41 \pm 16.88	–	a) -13.72 (-20.70– -6.74), -1.06** b) – c) –
PPSA UB, %	12.47 \pm 10.05	14.08 \pm 10.19	–	a) -1.62 (-6.95– -3.72), -0.16 b) – c) –
PCS	13.37 \pm 9.97	20.33 \pm 12.50	12.65 \pm 9.50	a) -6.96 (-14.13– -0.20), -0.62 b) 0.72 (-6.51– -7.95), 0.07 c) -7.68 (0.45– 14.91), 0.69*
A-state	16.38 \pm 9.56	20.55 \pm 9.94	10.30 \pm 8.45	a) -4.17 (-10.70– 2.36), -0.43 b) 6.08 (-0.40– 12.56), 0.67 c) 10.25 (4.32– 16.18), 1.11**
A-trait	17.40 \pm 8.82	22.52 \pm 9.29	14.43 \pm 7.94	a) -5.12 (-11.47– 1.23), -0.56 b) 2.97 (-3.15– 9.08), 0.35 c) 8.09 (2.35– 13.82), 0.94*

A-state, state anxiety; A-trait, trait anxiety; CI, confidence interval; CNP, chronic neck pain; PCS, pain catastrophizing scale; PPSA, percentage pain surface area; TMD, temporomandibular disorder; UB, upper body.

*P<0.05

**P <0.01

Table 3. Descriptive data and multiple comparisons of the pressure-pain threshold variable.

	Mean \pm SD			ANOVA inter- groups η^2_p	Mean difference (95% CI), effect size (<i>d</i>)	
	CNP	TMD+CNP	Asymptomatic		a) CNP vs TMD+CNP	b) CNP vs asymptomatic
C2, kg/cm ²	1.60 \pm 0.68	1.34 \pm 0.75	2.29 \pm 0.99	F = 17.28, P < 0.01 η^2_p = 0.29	a) 0.26 (-0.27– 0.80), 0.36 b) -0.69 (-1.22– -0.16), -0.81** c) -0.96 (-1.47– -0.43), -1.08**	
Right masseter, kg/cm ²	1.16 \pm 0.44	0.79 \pm 0.48	1.51 \pm 0.49	F = 17.28, P < 0.01 η^2_p = 0.29	a) 0.37 (0.06– 0.68), 0.80* b) -0.35 (-0.66– -0.04), -0.75* c) -0.72 (-1.02– -0.42), -1.48**	
Left masseter, kg/cm ²	1.10 \pm 0.48	0.71 \pm 0.39	1.47 \pm 0.62	F = 16.49, P < 0.01 η^2_p = 0.28	a) 0.38 (0.52– 0.71), 0.89* b) -0.38 (-0.70– -0.05), -0.67* c) -0.76 (-1.08– -0.44), -1.47**	
Right temporal, kg/cm ²	1.44 \pm 0.67	1.05 \pm 0.59	1.97 \pm 0.91	F = 11.39, P < 0.01 η^2_p = 0.21	a) 0.39 (-0.09– 0.87), 0.62 b) -0.53 (-1.01– -0.05), 0.66* c) -0.92 (-1.39– -0.45), -1.20**	
Left temporal, kg/cm ²	1.30 \pm 0.57	0.99 \pm 0.59	1.87 \pm 0.82	F = 12.92, P < 0.01 η^2_p = 0.24	a) 0.32 (-0.13– 0.76), 0.53 b) -0.57 (-1.00– -0.13), -0.81** c) -0.88 (-1.31– -0.45), -1.23**	
Right trapezius, kg/cm ²	1.77 \pm 0.76	1.34 \pm 0.61	2.24 \pm 0.77	F = 11.71, P < 0.01 η^2_p = 0.22	a) 0.44 (-0.32– 0.91), 0.62 b) -0.47 (-0.93– -0.00), -0.61* c) -0.91 (-1.36– -0.45), -1.30**	
Left trapezius, kg/cm ²	1.72 \pm 0.67	1.29 \pm 0.60	2.35 \pm 0.97	F = 14.17, P < 0.01 η^2_p = 0.25	a) 0.43 (-0.07– 0.94), 0.68** b) -0.63 (-1.13– -0.13), -0.76** c) -1.06 (-1.55– -0.57), -1.31**	
Right tibialis, kg/cm ²	4.51 \pm 1.65	3.04 \pm 1.32	5.70 \pm 2.54	F = 14.19, P < 0.01 η^2_p = 0.25	a) 1.47 (0.22– 2.72), 0.98* b) -1.19 (-2.43– -0.06), -0.56 c) -2.66 (-3.88– -1.44), -1.31**	
Left tibialis, kg/cm ²	4.36 \pm 1.52	3.02 \pm 1.31	5.19 \pm 2.72	F = 9.01, P < 0.01 η^2_p = 0.18	a) 1.34 (0.05– 2.63), 0.94* b) -0.82 (-2.10– -0.45), -0.38 c) -2.16 (-3.42– -0.91), -1.02**	

C2, spinous process of the second cervical vertebra; CI, confidence interval; CNP, chronic neck pain; TMD, temporomandibular disorder; UB, upper body.

*P < 0.05

**P < 0.01

Table 4. Pearson correlation coefficient for all outcomes in patient groups.

	Chronicity	Age	NPRS	PCS	A-state	A-trait	Group
Widespread pain UB	–	0.056	0.394	0.260	0.448*	0.058	CNP
	0.552**	0.446*	0.226	0.134	0.245	0.417*	TMD+CNP
NDI	–	-0.321	0.204	0.494**	0.466*	0.547*	CNP
	0.337*	0.182	0.107	0.404*	0.222	0.555**	TMD+CNP
C2	–	0.389*	-0.494*	-0.169	-0.292	0.011	CNP
	0.036	-0.110	0.141	-0.281	-0.043	0.138	TMD+CNP
Left masseter	–	0.406*	-0.468*	-0.251	-0.171	-0.064	CNP
	0.026	-0.148	-0.048	-0.171	-0.107	-0.199	TMD+CNP
Right masseter	–	0.363	-0.446*	-0.316	-0.236	-0.136	CNP
	-0.019	-0.111	0.113	-0.329	-0.175	-0.094	TMD+CNP
Left temporal	–	0.403*	-0.295	-0.199	-0.100	-0.019	CNP
	-0.023	-0.187	-0.072	-0.361	-0.185	-0.171	TMD+CNP
Right temporal	–	0.396*	-0.447*	-0.202	-0.215	-0.070	CNP
	-0.131	-0.223	0.057	-0.336	-0.101	-0.035	TMD+CNP
Left trapezius	–	0.334	-0.355	-0.187	-0.257	-0.014	CNP
	-0.126	-0.060	-0.275	-0.336	-0.011	-0.105	TMD+CNP
Right trapezius	–	0.230	-0.416	-0.183	0.232	0.064	CNP
	-0.104	-0.027	-0.222	-0.318	-0.063	-0.128	TMD+CNP
Left tibialis	–	0.480*	-0.378	-0.636**	-0.232	-0.238	CNP
	0.00	-0.091	-0.137	-0.318	-0.261	-0.037	TMD+CNP
Right tibialis	–	0.452*	-0.431	-0.592**	-0.288	-0.207	CNP
	0.125	-0.058	-0.176	-0.422*	-0.219	0.076	TMD+CNP

A-state, state anxiety; A-trait, trait anxiety; C2, spinous process of the second cervical vertebra; CNP, chronic neck pain; NDI, Neck Disability Index; NPRS, numerical pain rating scale; PCS, Pain Catastrophizing Scale; temporomandibular disorder; UB, upper body.

*P<0.05

**P <0.01